𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

✍ Scribed by Beale, P; Judson, I; O'Donnell, A; Trigo, J; Rees, C; Raynaud, F; Turner, A; Simmons, L; Etterley, L

Book ID
109997529
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
123 KB
Volume
88
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

5-fluorouracil and cis-platinum in the t
5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I β€” II study
✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.

Phase I clinical trial of combined thera
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and cis-platinum (II) diaminedichloride (NSC 119875)
✍ Richard A. Ellerby; Hugh L. Davis Jr.; Fred J. Ansfield; Guillermo Ramirez πŸ“‚ Article πŸ“… 1974 πŸ› John Wiley and Sons 🌐 English βš– 438 KB

Thirty-one loading courses of 5-FU and cis-platinum (11) diaminedichloride (CPD) were given to 27 patients with a variety of malignancies. Up to 16 mg/kg/day of 5-FU and 2.5 mg/kg of the platinum were reached with minimal toxicity. Nausea (27/31) and vomiting (23/31) were the most frequent symptoms,